<p>Ken Tassey, president of <a class="link" rel="nofollow" target="_blank" href="http://www.bostonti.com/" target="_blank">Boston Therapeutics, Inc.</a> <a class="link" rel="nofollow" target="_blank" href="https://www.google.com/finance?cid=1032014066834765" target="_blank">(OTCQB: BTHE)</a>, discusses enrolling patients in a Phase IIb clinical study on <a class="link" rel="nofollow" target="_blank" href="http://www.bostonti.com/product-pipeline/paz320" style="font-size: 13px;" target="_blank">PAZ320</a>, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. A total of 24 patients with Type 2 diabetes currently being treated with metformin will be administered PAZ320 under double-blind, placebo-controlled conditions, <a class="link" rel="nofollow" target="_blank" href="http://www.bostonti.com/product-pipeline/paz320" style="font-size: 13px;" target="_blank">according to Boston Therapeutics</a>.</p><p>“This trial is designed to build upon the positive results from our Dartmouth Medical Center Phase IIa trial for PAZ320, recently published in the peer-reviewed journal, Endocrine Practice,” said David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics in a <a class="link" rel="nofollow" target="_blank" href="http://ir.stockpr.com/bostonti/press-releases/detail/474/" target="_blank">press release</a>. “In the Phase IIa study, PAZ320 was well tolerated in patients taking various anti-diabetic agents, including metformin. The Phase IIb trial, which focuses on patients taking only metformin, is the next step in the investigation of this compound as a potential adjunct to metformin in patients living with Type 2 diabetes. We believe it is important to better control glucose levels throughout the day, given the many complications that stem from uncontrolled diabetes.”</p><p>The company said PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose.</p>
